Business Context and Reporting Period
This Form 6-K filing by Mainz Biomed N.V. (noted as Quantum Cyber N.V. in metadata) covers the month of October 2025, with a specific reporting date of October 3, 2025. The registrant is a foreign private issuer headquartered in Mainz, Germany, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is a report of a material agreement rather than a financial results statement.
Material Changes and Agreements
On October 3, 2025, the company entered into an Equity Distribution Agreement (Sales Agreement) with Maxim Group LLC. Key terms include:
- Offering Size: Up to $10,000,000 aggregate offering amount of ordinary shares.
- Initial Shelf Capacity: Up to $2,300,000 of the offered shares may be sold under the existing effective shelf registration statement (Form F-3, File No. 333-269091).
- Sale Method: "At-the-market" offerings on the Nasdaq Capital Market or other permitted methods, including block trades.
- Compensation: The company will pay Maxim Group LLC a commission of 3.0% of the gross sales price.
- Obligation: The company is not obligated to sell any shares; the agreement terminates upon the sale of all shares or earlier termination by either party.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. The primary contingency noted is the discretionary nature of the share sales; the company may elect not to sell any shares under the agreement. The document includes standard legal disclaimers stating it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price and trading volume on the Nasdaq Capital Market to assess the potential dilution impact of a $10,000,000 offering.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific termination rights and expense reimbursement details.
- Confirm the status of the underlying Form F-3 shelf registration (File No. 333-269091) to ensure the $2,300,000 initial tranche is fully available.
- Check for any subsequent filings indicating the actual execution of share sales under this agreement.